Gomco Pharma

A medication containing Dicyclomine HCl 10 mg and Simethicone 40 mg is a combination drug used primarily to relieve abdominal pain, cramps, bloating, and gas associated with gastrointestinal issues, including irritable bowel syndrome (IBS). Active Ingredients and Mechanism of Action

• Dicyclomine Hydrochloride (10 mg): This is an antispasmodic and anticholinergic agent. It works by relaxing the smooth muscles in the wall of the stomach and intestines, which stops sudden muscle contractions (spasms) and relieves abdominal pain and cramping.
• Simethicone (40 mg): This is an anti-foaming medicine or defoaming agent. It works by breaking down and dispersing gas bubbles that are trapped in the stomach and intestines, allowing the gas to be passed more easily, thereby reducing bloating and discomfort. 

Key UsesThis combination medication is commonly used to treat: 

• Irritable Bowel Syndrome (IBS) symptoms
• Abdominal pain and spasms/cramps
• Excessive gas, bloating, and flatulence
• Infantile colic (in appropriate formulations and as directed by a pediatrician) 

Important Considerations

• Prescription: This medication is generally available by prescription only.
• Administration: It is often available in various forms such as drops, suspension (syrup), capsules, or tablets. The specific dosage and form should be determined by a healthcare provider based on the patient's age, weight, and condition.
• Side Effects: Common side effects can include dry mouth, dizziness, drowsiness, nausea, and blurred vision. Patients should use caution while driving or operating machinery.
• Contraindications: It should not be used in infants under 6 months of age, in patients with glaucoma, myasthenia gravis, or certain obstructive diseases of the gastrointestinal tract.
• Alcohol: Alcohol consumption should be avoided as it can increase drowsiness and the risk of stomach problems. 

Always consult a healthcare professional or pharmacist for specific medical advice, dosage instructions, and a full list of warnings and potential drug interactions.